Trastuzumab biosimilar (MYL-14010) shown effective in breast cancer clinical trial

Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA. Trstuzumab Biosimilars Biological agents, including monoclonal antibodies, have increased the treatment options and greatly improved …

Trastuzumab biosimilar (MYL-14010) shown effective in breast cancer clinical trial Read More »